Prognostic impact of hs-CRP and IL-6 in patients undergoing radiofrequency catheter ablation for atrial fibrillation

Scandinavian Cardiovascular Journal

Volumn 43, Issue 5, 2009, Pages 285-291

  Henningsen, Kristoffer Mads Aaris ^a   Nilsson, Brian ^a   Bruunsgaard, Helle ^b   Chen, Xu ^a   Pedersen, Bente Klarlund ^b   Svendsen, Jesper Hastrup ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; AUTACOID; BIOLOGICAL MARKER; IL6 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CATHETER ABLATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HOLTER MONITORING; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY VEIN; SINUS RHYTHM; SUPRAVENTRICULAR TACHYCARDIA; ATRIAL FIBRILLATION; BLOOD; CHI SQUARE DISTRIBUTION; DENMARK; ELECTROCARDIOGRAPHY; IMMUNOLOGY; MIDDLE AGED; RECURRENT DISEASE; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; UPREGULATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CATHETER ABLATION; CHI-SQUARE DISTRIBUTION; DENMARK; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MIDDLE AGED; RECURRENCE; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 70350074785     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.1080/14017430802653676     Document Type: Article

References (25)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995;155:469-73.
2. Friberg J, Scharling H, Gadsboll N, Jensen GB. Sex-specific increase in the prevalence of atrial fibrillation (The Copenhagen City Heart Study). Am J Cardiol. 2003;92:1419-23. (Pubitemid 37532563)
3. Levy S, Camm AJ, Saksena S, Aliot E, Breithardt G, Crijns HJ, et al. International consensus on nomenclature and classification of atrial fibrillation: A collaborative project of the Working Group on Arrhythmias and the Working Group of Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. J Cardiovasc Electrophysiol. 2003;14:443-5. (Pubitemid 36529038)
4. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96:1180-4.
5. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995;92:1954-68.
6. Chung MK,Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, et al. C-reactive protein elevation in patients with atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001;104:2886-91.
7. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J. 2005;26: 2083-92.
8. Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Kolyvaki SG, Lyrarakis GM, et al. The role of the postcardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation. Heart. 2008;94:200-4.
9. Loricchio ML, Cianfrocca C, Pasceri V, Bianconi L, Auriti A, Calo L, et al. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol. 2007;99:1421-4.
10. Watanabe E, Arakawa T, Uchiyama T, Kodama I, Hishida H. High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int J Cardiol. 2006;108:346-53.
11. Nilsson B, Chen X, Pehrson S, Kober L, Hilden J, Svendsen JH. Recurrence of pulmonary vein conduction and atrial fibrillation after pulmonary vein isolation for atrial fibrillation: A randomized trial of the ostial versus the extraostial ablation strategy. Am Heart J. 2006;152:537-8.
12. Haissaguerre M, Jais P, Shah DC, Garrigue S, Takahashi A, Lavergne T, et al. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. Circulation. 2000;101:1409-17.
13. Pappone C, Oreto G, Rosanio S, Vicedomini G, Tocchi M, Gugliotta F, et al. Atrial electroanatomic remodeling after circumferential radiofrequency pulmonary vein ablation: Efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation. Circulation. 2001;104:2539-44.
14. McCabe JM, Smith LM, Tseng ZH, Badhwar N, Lee BK, Lee RJ, et al. Protracted CRP elevation after atrial fibrillation ablation. Pacing Clin Electrophysiol. 2008;31:1146-51.
15. Liuba I, Ahlmroth H, Jonasson L, Englund A, Jonsson A, Safstrom K, et al. Source of inflammatory markers in patients with atrial fibrillation. Europace. 2008;10:848-53.
16. Marcus GM, Smith LM, Glidden DV, Wilson E, McCabe JM, Whiteman D, et al. Markers of inflammation before and after curative ablation of atrial flutter. Heart Rhythm. 2008;5: 215-21.
17. Bruins P, te VH, Yazdanbakhsh AP, Jansen PG, van Hardevelt FW, de Beaumont EM, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: Postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997; 96:3542-8.
18. Holm T, Andreassen AK, Ueland T, Kjekshus J, Froland SS, Kjekshus E, et al. Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. Am J Cardiol. 2001;87:815-8, A9.
19. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358: 1431-43.
20. Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM, et al. Simvastatin lowers C-reactive protein within 14 days: An effect independent of low-density lipoprotein cholesterol reduction. Circulation. 2002;106: 1447-52.
21. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999;100:230-5.
22. Tveit A, Grundvold I, Olufsen M, Seljeflot I, Abdelnoor M, Arnesen H, et al. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol. 2007;120:85-91.
23. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J. 2004;25:1100-7.
24. Fauchier L, Pierre B, de LA, Grimard C, Zannad N, Babuty D. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2008;51:828-35.
25. Piorkowski C, Kottkamp H, Tanner H, Kobza R, Nielsen JC, Arya A, et al. Value of different follow-up strategies to assess the efficacy of circumferential pulmonary vein ablation for the curative treatment of atrial fibrillation. J Cardiovasc Electrophysiol. 2005;16:1286-92.